Choroidal thickness postural changes in healthy young adults.
Choroidal thickness postural changes in healthy young adults.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Salerno, IT · Author affiliation
Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, SA, Italy.Location evidence
Eboli, IT · Author affiliation
Eye Unit, Maria SS Addolorata Hospital, ASL Salerno, Eboli, SA, Italy. marco.gioia@yahoo.it.Location evidence
Castellammare di Stabia, IT · Author affiliation
Eye Unit, San Leonardo Hospital, ASL NA 3, Castellammare di Stabia, NA, Italy.Location evidence
IT · Author affiliation · country only
Eye Unit, Pellegrini Hospital, ASL Napoli 1, Napoli, NA, Italy.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
The purpose of this study was to evaluate choroidal thickness (ChT) postural changes between sitting and standing position in healthy young adults. 100 patients, 56 males and 44 females (mean age 26,8 ± 2 years) underwent a complete eye examination, including ChT, axial length (AL) and IOP measurements. ChT measurement was performed in sitting and standing positions. In OD, mean subfoveal ChT was 279 μm ± 96 μm in sitting position and 267 μm ± 94 μm in standing position (p < 0.001); mean nasal ChT was 224 μm ± 88 μm in sitting position and 214 μm ± 88 μm in standing position (p < 0.001); mean temporal ChT was 287 ± 84 μm in sitting position and 275 μm ± 82 μm in standing position (p < 0.001). We demonstrated that, when subjects change their position from sitting to standing, a thinning in ChT is detected. The physiology behind the described variations is still incompletely understood and may be tied to the activation of the baroreceptor reflex caused by postural changes. More studies should be performed to prove the usefulness of ChT variation as a biomarker in autonomic nervous system (ANS) diseases, such as Multiple system atrophy (MSA) and Parkinson's disease (PD).